Apotex Health Corp. · TSX:APTX

Apotex Health — Q2 FY2027 Earnings Presentation

27 slides from Apotex Health's earnings presentation, November 2026

  1. Slide 1: Second Quarter Fiscal 2027 Earnings

    SECOND QUARTER FISCAL 2027 EARNINGS

  2. Slide 2: Disclaimer

    DISCLAIMER Cautionary Note Regarding Forward-Looking Information This presentation contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information may relate to Apotex

  3. Slide 3: Agenda and Today's Participants

    SECOND QUARTER FISCAL 2027 EARNINGS CALL Agenda Today’s Participants CEO Business Review 1 Jeff Watson, President & CEO Jeff Watson Brian McClelland President & Chief Chief Financial Executive Officer Officer Financial Performance Review 2 Brian McClelland, CFO Christine Martin Arès Baeder President

  4. Slide 4: CEO Business Review

    CEO BUSINESS REVIEW APOTEX

  5. Slide 5: Delivering Results Through Journey of Health Strategy: Highlights

    DELIVERING RESULTS THROUGH JOURNEY OF HEALTH STRATEGY: HIGHLIGHTS Operational Execution Financial Performance Launches and Approvals Fiscal 2027 Guidance3 ▪ Productivity initiatives on track with ▪ Strong Q2 2027, with results above ▪ Launched ~60 products in first half ▪ Raising guidance following

  6. Slide 6: Revenue Mix Performance

    REVENUE MIX Q2 Market Segment Mix1 International 8%, -100 bps PERFORMANCE 49% Canada Market segment revenue mix reflects 43% +5% Canada 49%, +400 bps the execution of the JOH strategy, led US US by continued strength in Canada driven 43%, -400 bps by portfolio diversification, launches and underlyin

  7. Slide 7: Strong Execution and First-to-Market

    STRONG EXECUTION AND 70% of launches were first-to-market(1,2) FIRST-TO-MARKET ENTRY DRIVE 12% Revenue in H1 driven by in-year launches STRONG RESULTS 56% were through external partnerships(1) ~60 Launches executed in H1 FY27 23 7 31 pharmaceutical Consumer Health international launches across and W

  8. Slide 8: GLP-1 Opportunity Remains Compelling

    GLP-1 OPPORTUNITY REMAINS COMPELLING DEMAND EXCEEDS EXPECTATIONS ▪ Apotex remains the sole generic supplier despite multiple supplier approvals. 19% Demand for Apo-Semaglutide Injection has exceeded expectations Semaglutide market1 expansion, RAMPING UP SUPPLY ahead of expectations ▪ Maximizing avai

  9. Slide 9: Business Development Update

    BUSINESS 28 product agreements1 in H1 FY27 DEVELOPMENT Estimated peak sales of over $500M Progress since Fiscal UPDATE 61% 2023 Specialty generics ~160 Expanding the product 39% products signed in the Brands & biosimilars past 4.5 years with pipeline to drive estimated peak sales of over $3B diversi

  10. Slide 10: Financial Performance Review

    FINANCIAL PERFORMANCE REVIEW 10

  11. Slide 11: Q2 Delivers Strong Performance Across Key Operating Metrics

    Q2 DELIVERS STRONG PERFORMANCE ACROSS KEY OPERATING METRICS In $CAD millions Q2 FY27 % Variance vs prior year1 5% Revenue 853 Gross Profit 445 11% +300 bps Gross Margin % 52% Strong performance across all KPIs Adjusted EBITDA2 280 19% +390 bps Adjusted EBITDA Margin % 32.8% Topline growth and streng

  12. Slide 12: Q2 Adjusted EBITDA Grows 19%

    Q2 ADJUSTED EBITDA GROWS 19% +19% +10% (9%) +18% 30 VLLP1 Tailwinds Launch performance, Most of the impact was Driven by Sales & marketing spend, 280 ~ 400 bps margin increase 235 productivity, one-time in including Cumberland favourable competitive nature due sales force conditions to prior year FX

  13. Slide 13: Canada Drives Q2 Revenue Growth

    CANADA DRIVES Q2 REVENUE GROWTH +5% +14% -3% -1% 30 VLLP1 813 853 Q2 26 Canada US International Q2 27 Canada United States International 49% of revenue 43% of revenue 8% of revenue ▪ Sustained strength of recent first-to-market launches in ▪ Decline reflects prior year contributions of nilotinib, a

  14. Slide 14: Continued Progress Toward Portfolio Diversification

    CONTINUED PROGRESS TOWARD PORTFOLIO DIVERSIFICATION +5% +11% -8% +18% 30 VLLP1 813 853 Q2 26 Conventional GX Specialty GX Brands & Biosimilars Q2 27 Conventional Generics Specialty Generics Brands & Biosimilars 48% of revenue 34% of revenue 18% of revenue ▪ Strong sales from recent first-to-market l

  15. Slide 15: Healthy Balance Sheet with Net Debt Leverage at 2.3x

    HEALTHY BALANCE SHEET WITH NET DEBT LEVERAGE AT 2.3X IN $CAD MILLIONS September 2026 March 2026 Variance Successful bond offering raised $1.25B in Debt Debt Debt reduction debt in October 2,352 2,940 following IPO Net Debt Leverage Ratio1 Debt proceeds reduced facility debt with 2.3x no increase in

  16. Slide 16: Apotex Fiscal 2027 Guidance

    APOTEX FISCAL 2027 GUIDANCE Updated Guidance Initial Guidance Drivers ▪ Strong operational performance in H1: launch Revenue Upper mid-single execution 9-10% growth growth3 digit growth (7-8%) ▪ Revenue growth acceleration in H2, including launch of axitinib in the U.S. ▪ Strong operational performa

  17. Slide 17: Delivering on Our Commitments as a Public Company

    DELIVERING ON OUR COMMITMENTS AS A PUBLIC COMPANY Executing against our Journey of Health strategy Delivered Q2 above expectations and upgraded FY27 guidance Strong Canadian performance and launch execution supported growth; momentum continues to build Executed key pipeline and launch initiatives ac

  18. Slide 18: Q&A

    Q&A

  19. Slide 19: Financial Statements and Supporting Schedules

    FINANCIAL STATEMENTS AND SUPPORTING SCHEDULES 19 Strictly Private and Confidential

  20. Slide 20: Interim Consolidated Statements of Net Income and Comprehensive Income

    INTERIM CONSOLIDATED STATEMENTS OF NET INCOME AND COMPREHENSIVE INCOME (in CAD millions) Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 Revenue $852.9 $843.5 $1,700.9 $1,985.8 Cost of sales 407.6 412.8 834.4 812.7 Gross profit $445.3 $430.7 $866.5 $1,173.1 Sellin

  21. Slide 21: Interim Consolidated Statements of Financial Position

    INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION September 30, September 30, (in CAD millions) March 31, 2026 (in CAD millions) March 31, 2026 2026 2026 Current assets Current liabilities Cash and cash equivalents $78.0 $57.0 Trade and other payables $1,098.3 $1,104.6 Trade receivables, net 882

  22. Slide 22: Interim Consolidated Statements of Cash Flows

    INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (in CAD millions) Six Months Ended September 30, (in CAD millions) Six Months Ended September 30, 2026 2025 2026 2025 Operating activities Investing activities Net income $62.4 $445.6 Proceeds from the sale of assets held for sale $38.4 $- Adjustments: P

  23. Slide 23: Reconciliation of Non-IFRS Measures – Adjusted EBITDA

    RECONCILIATION OF NON-IFRS MEASURES – ADJUSTED EBITDA 1) Represents advisory fees and other expenses paid to third (in CAD millions) Three Months Ended September 30, Six Months Ended September 30, parties related to business acquisition and integration activities. 2026 2025 2026 2025 These fees and

  24. Slide 24: Reconciliation of Non-IFRS Measures – Net Debt & Adjusted Net Income

    RECONCILIATION OF NON-IFRS MEASURES – NET DEBT & ADJUSTED NET INCOME NET DEBT 1) Represents advisory fees and other expenses paid to third parties related to business acquisition and integration September 30, activities. These fees and expenses are excluded from (in CAD millions) March 31, 2026 Adju

  25. Slide 25: Reconciliation of Non-IFRS Measures – Operating Free Cash Flow

    RECONCILIATION OF NON-IFRS MEASURES – OPERATING FREE CASH FLOW (in CAD millions) Six Months Ended September 30, 1) Represents periodic rent payments made by the Company, as applicable, to the lessor in exchange 2026 2025 of the right to use the leased asset over the reporting period. Net cash flows

  26. Slide 26: Various Measures Excluding the Impact of the U.S. Contribution of VLLP

    VARIOUS MEASURES EXCLUDING THE IMPACT OF THE U.S. CONTRIBUTION OF THE VOLUME-LIMITED LICENSE PRODUCT (“VLLP”) (in CAD millions) Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 Revenue $852.9 $843.5 $1,700.9 $1,985.8 U.S. Contribution of VLLP - (30.4) - (338.2) Rev

  27. Slide 27: Various Measures Excluding the Impact of VLLP (Continued)

    VARIOUS MEASURES EXCLUDING THE IMPACT OF THE U.S. CONTRIBUTION OF THE VLLP (CONTINUED) (in CAD millions) Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 U.S. Gross profit $187.3 $214.4 $376.4 $721.3 U.S. Contribution of VLLP - (30.3) - (337.8) U.S. Gross Profit ex

Apotex Health — Q2 FY2027 Earnings Presentation on 6ix